Drugs / human umbilical cord blood (hUCB)-derived mesenchymal stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03378063 | Nov 2017 → Dec 2022 | bronchopulmonary dysplasia | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human umbilical cord blood (hUCB)-derived mesenchymal stem cell | “allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants” NCT03378063 ↗ |
| Known as | MSC | “allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants” NCT03378063 ↗ |
| Modality | Cell therapy | “transplantation of mesenchymal stem cell” NCT03378063 ↗ |